POZEN Logo
Print Page   Close Window

Press Release

Pozen to Present at UBS Global Life Sciences Conference

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Sept. 13, 2005--POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will be speaking to investors at the UBS Global Life Sciences Conference on Tuesday, September 27, 2005 at 10:30 a.m. Eastern Time in New York City. Dr. Plachetka's presentation will be webcast and archived on POZEN's home page at www.pozen.com.

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN has development and commercial alliances with GlaxoSmithKline, Valeant Pharmaceuticals North America, a subsidiary of Valeant Pharmaceuticals International (formerly Xcel Pharmaceuticals, Inc.), and Nycomed Danmark ApS. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

CONTACT:
POZEN Inc.
Bill Hodges, Chief Financial Officer
919-913-1030
Fran Barsky, Director, Investor Relations
919-913-1044

SOURCE: POZEN Inc.